Multi-Component Medication for Nausea and Vertigo Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current over-the-counter medications do not comprehensively address nausea, vomiting, vertigo, and pain across various medical conditions, lacking versatility in symptom treatment and combination therapy.
Innovation Solution
A medication combination featuring antihistamines or antiemetics like diphenhydramine, meclizine, and ondansetron, paired with analgesics such as acetaminophen, ibuprofen, and nasal decongestants, cough suppressants, and expectorants, allowing for interchangeable combinations to treat a range of symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current over-the-counter medications are used, then specific symptoms may be treated, but comprehensive coverage across multiple symptoms and medical conditions is not achieved
Solution Approach 1:
The patent creates a universal medication system where multiple antiemetics (diphenhydramine, meclizine, dimenhydrinate, cyclizine, betahistine, cinnarizine, promethazine, metoclopramide, prochlorperazine, ondansetron) can be combined with various analgesics (acetaminophen, ibuprofen, naproxen, aspirin, ketorolac) and adjuvants (caffeine, phenylephrine, pseudoephedrine, dextromethorphan, guaifenesin) to treat a comprehensive range of symptoms including nausea, vomiting, vertigo, pain, nasal congestion, cough, and chest congestion across multiple medical conditions. This multi-functional approach allows a single medication system to address diverse symptom combinations without requiring separate specialized treatments for each condition.
Solution Approach 2:
The patent segments the medication system into distinct functional modules: antiemetic agents, analgesics, and adjuvants. Each module can be independently selected and combined based on the specific symptoms being treated. For example, a patient experiencing nausea and vertigo would receive meclizine and cyclizine from the antiemetic module, while a patient with nausea and headache would receive meclizine combined with acetaminophen and ibuprofen from the analgesic module. This segmentation allows for customized treatment regimens that can be easily adjusted to match individual patient needs and symptom profiles.
2Adaptability or versatility
If multiple medications are combined to treat various symptoms, then comprehensive symptom relief is achieved, but treatment flexibility and adaptability are reduced
Solution Approach 1:
The patent implements a dynamic medication selection system where the specific combination of antiemetics, analgesics, and adjuvants can be adjusted based on the patient's individual symptoms, medical history, and response to treatment. The system allows for real-time modification of the medication regimen - for instance, starting with a simpler combination and adding components only as needed, or adjusting doses and frequencies based on symptom progression. This dynamic approach maintains treatment flexibility while managing the complexity of multiple medication components through systematic organization and clinical guidance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination provides broad-spectrum symptom relief for nausea, vomiting, vertigo, pain, and associated symptoms across various medical conditions, offering flexibility in treatment options and accommodating different patient needs.
Implementation Method 1
The anti-emetics included are diphenhydramine, meclizine, dimenhydrinate, cyclizine, betahistine, cinnarizine, promethazine; metoclopramide; prochlorperazine; and the antiemetic ondansetron which is a serotonin 5-HT3 receptor antagonist
Implementation Method 2
the antiemetic ondansetron which is a serotonin 5-HT3 receptor antagonist
Implementation Method 3
with or without an analgesic(s) such as acetaminophen with or without caffeine and with or without aspirin, acetaminophen as a single entity by itself; acetaminophen in combination with ibuprofen; acetaminophen in combination with naproxen; aspirin; ibuprofen; naproxen; ketorolac
Implementation Method 4
with or without a nasal decongestant phenylephrine including any reformulated version of phenylephrine or pseudoephedrine
Implementation Method 5
with or without a cough suppressant such as dextromethorphan hydrobromide or dextromethorphan polistirex
Implementation Method 6
with or without an expectorant guaifenesin
Data Source
AI summary
This invention is new because no prior art discusses using any of these antiemetics as a single entity medication or in combination with any analgesic(s) for the indication of nausea with or without vomiting; vertigo including MAV, photophobia, phonophobia, with or without pain. This invention also differs from prior art in that the aforementioned antiemetics in any combination with the aforementioned analgesic(s), are also able to combined with or without a nasal decongestant dextromethorphan guaifenesin. The interchangeability of the drugs and doses allows for versatility which prior art does not offer. Actual dosages used will be within that range at therapeutic, efficacious, and safe dosages in subjects for the treatment of the indication(s) being claimed and/or exhibited by subjects. Utilizing subtherapeutic and supratherapeutic doses in the ranges are not obvious or usual doses utilized by people knowledgeable in the prior art, differentiating it from prior art and supporting patentability.